WB analysis of 30 μg of A431 (Lane 1) treated with EGF (200 ng/ml for 10 minutes) (Lane 2), treated with Afatinib followed by EGF (0.5 uM of Afatinib for 6hrs, 200ng/ml for 10 minutes) (Lane 3), EGFR KO A431(Lane 4) treated with EGF (200 ng/ml for 10 minutes) (Lane 5), EGFR KO A431 treated with Afatinib followed by EGF (0.5 uM of Afatinib for 6hrs, 200ng/ml for 10 minutes) (Lane 6) whole cell extracts using GTX24890 SHC1 (phospho Tyr239/Tyr240) antibody.
Dilution : 1:500

WB analysis of membrane enriched extracts (30 ug lysate) of A431 (Lane 1), A431 treated with EGF (200 ng/ml for 10 minutes) (Lane 2), A431 treated with Afatinib followed by EGF (0.5 uM for 6 hours, 200ng/ml for 10 minutes) (Lane 3), A549 (Lane 4), A549 treated with EGF (200 ng/ml for 10 minutes) (Lane 5) using GTX24890 SHC1 (phospho Tyr239/Tyr240) antibody.
Dilution : 1:500

WB analysis of A431 stimulated with EGF (Lane 1-4) or left unstimulated (Lane 5) using GTX24890 SHC1 (phospho Tyr239/Tyr240) antibody.

IHC-P analysis of human colon carcinoma tissue using GTX24890 SHC1 (phospho Tyr239/Tyr240) antibody.
Right : Primary antibody
Left : Negative control without primary antibody
Antigen retrieval : 10mM sodium citrate (pH 6.0), microwaved for 8-15 min
Dilution : 1:20

WB analysis of whole cell extracts (20 μg lysate) of A431 (Lane 1), treated for 10 minutes with 200 ng/ml of EGF (Lane 2), NIH/3T3 (Lane 3) and treated for 10 minutes with 200 ng/ml of EGF (Lane 4) using GTX24890 SHC1 (phospho Tyr239/Tyr240) antibody.
Dilution : 1:500